Literature DB >> 22850719

Chemoprotection in brain tumor patients: another success for stem cell gene therapy.

Brian P Sorrentino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22850719      PMCID： PMC3412487          DOI： 10.1038/mt.2012.139

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  15 in total

1.  LMO2 and gene therapy for severe combined immunodeficiency.

Authors:  Alain Fischer; Salima Hacein-Bey Abina; Adrian Thrasher; Christof von Kalle; Marina Cavazzana-Calvo
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

2.  Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.

Authors:  N Sawai; S Zhou; E F Vanin; P Houghton; T P Brent; B P Sorrentino
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

3.  Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy.

Authors:  Tobias Neff; Brian C Beard; Laura J Peterson; Ponni Anandakumar; Jesse Thompson; Hans-Peter Kiem
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

4.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

5.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

6.  Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jeremy N Rich; Sridharan Gururangan; Allan H Friedman; Darell D Bigner; John H Sampson; Roger E McLendon; James E Herndon; Amy Walker; Henry S Friedman
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.

Authors:  Andre Larochelle; Uimook Choi; Yan Shou; Nora Naumann; Natalia A Loktionova; Joshua R Clevenger; Allen Krouse; Mark Metzger; Robert E Donahue; Elizabeth Kang; Clinton Stewart; Derek Persons; Harry L Malech; Cynthia E Dunbar; Brian P Sorrentino
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

8.  Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.

Authors:  Huifen Zhao; Tamara I Pestina; Md Nasimuzzaman; Perdeep Mehta; Phillip W Hargrove; Derek A Persons
Journal:  Blood       Date:  2009-04-13       Impact factor: 22.113

9.  Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.

Authors:  Caroline Happold; Patrick Roth; Wolfgang Wick; Natalie Schmidt; Ana-Maria Florea; Manuela Silginer; Guido Reifenberger; Michael Weller
Journal:  J Neurochem       Date:  2012-05-28       Impact factor: 5.372

Review 10.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544
View more
  1 in total

Review 1.  Neurocognitive functioning and genetic variation in patients with primary brain tumours.

Authors:  Jeffrey S Wefel; Kyle R Noll; Michael E Scheurer
Journal:  Lancet Oncol       Date:  2016-03-02       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.